Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A collaborative study led by the OPDC's Dr Nora Bengoa-Vergniory has shown that compounds known as molecular tweezers could become a promising disease modifying therapy for Parkinson’s.

A team of researchers has shown that tiny compounds known as molecular “tweezers” could become a promising therapy to slow Parkinson’s. This new kind of drug works by pulling apart toxic clumps of protein that form in the brain during Parkinson’s.

The therapy has previously shown high potential for targeting toxic protein clumps that form in neurodegenerative conditions such as Alzheimer’s. The research teams therefore investigated whether a particular molecular tweezer, CLR01, was able to reduce formation of protein clumps in cell and mouse models of Parkinson’s.

The research was led by the Oxford Parkinson’s Disease Centre at the University of Oxford, created through funding from Parkinson’s UK, and supported by the Medical Research Council with collaborators from the University of Bordeaux, the Universidad del País Vasco and the University of California.

The study showed that CLR01 is able to decrease clusters of the Parkinson’s protein alpha-synuclein forming and prevent the death of human neurons that were made from stem cells.

Researchers tested CLR01 in a mouse model of Parkinson’s that stimulates the formation of protein clusters and mimics the motor symptoms experienced by people with the condition, which can include tremor and slowness of movement. As the mice aged, CLR01 treatment reduced the appearance of motor problems and the formation of toxic protein clusters in the brain. Importantly, the team showed that in much older animals with more progressed Parkinson’s, CLR01 treatment was less effective.

This work shows that using protective therapies early on in Parkinson’s is essential for an effective treatment. These combined results highlight that CLR01 represents a candidate to treat Parkinson’s, and highlights the need for further research in this area.

Lead Researcher Dr Nora Bengoa-Vergniory said: “Future investment to determine the appropriate therapeutic window for these kinds of therapeutic agents is crucial for the success of these and other therapeutic strategies.”

Head of the Oxford Parkinson’s Disease Centre and senior author on the study Professor Richard Wade-Martins said: “This is a very exciting piece of work showing that drug treatments can be developed to unpick toxic protein clusters to save neurons in models of Parkinson’s. Our work is focused on developing new approaches to saving neurons when they start to lose function early on, but before they die later on in the condition. This is a very exciting piece of work showing that drug treatments can be developed to unpick toxic protein clusters to save neurons in models of Parkinson’s. This work should give encouragement to those ultimately hoping for protective therapies.”

Dr Beckie Port, Research Manager at Parkinson’s UK, said: "We desperately need treatments that protect brain cells in Parkinson's. These findings show that this innovative 'molecular tweezer' approach has exciting potential in the lab. We now need to take this therapy forward to test in clinical trials - only then will we know whether it can do the same in people with Parkinson's."

 

The research paper “CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease is published in Nature Communications.

This story has been featured in The Times: "Brain 'tweezers' could treat Parkinson's".

Similar stories

Collaborating with Youth is Key to Studying Mental Health Management

Research Highlights

The Global Mental Health Databank, a feasibility study, hopes to enable youth from the United Kingdom, South Africa, and India to work directly with mental health researchers to better understand how young people can manage their own mental health.

SSRI Treatment in Young People with Depression and Anxiety

Research Highlights

Results from an insight review commissioned by the Wellcome Trust, highlights what is currently known about the benefits and risks of using selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression and anxiety in young people.

The brain understands relationships in the same way as it understands how to move in space

Research Highlights

Researchers led by a team at the Wellcome Centre for Integrative Neuroimaging at the University of Oxford have developed a new framework that binds together the way the brain forms maps of space to the way the brain understands relationships of any kind – general mental maps.

Researchers reveal surprising simplicity behind our ability to hear

Research Highlights

A computational modelling study from the King Group demonstrates that the way sounds are transformed from the ear to the brain’s auditory cortex may be simpler than expected. These findings not only highlight the value of computational modelling for determining the principles underlying neural processing, but could also be useful for improving treatments for patients with hearing loss.